Post Profile

AstraZeneca licenses respiratory drug to Insmed

(Reuters) - Drugmaker Insmed Inc said it on Wednesday it had bought the rights to an experimental early-stage respiratory drug from Britain's AstraZeneca Plc in a deal worth $150 million.
read more


Related Posts

Summit and Sarepta to collaborate on muscular dystrophy drug

Health : Reuters: Health

(Reuters) - Drugmaker Sarepta Therapeutics Inc has entered into an exclusive license agreement with Britain's Summit Therapeutics Plc to develop drugs to treat Duchenne muscular dystrophy (DMD), the companies said on Tuesday.

AstraZeneca in talks to buy private drugmaker Acerta Pharma: WSJ

Business & Finance : Business Insider: Clusterstock

(Reuters) - British drugmaker AstraZeneca Plc is in advanced talks to buy privately held drug developer Acerta Pharma BV for more than $5 billion, the Wall Street Journal reported, citing people familiar with the matter. Netherlands...

Bristol, AstraZeneca among Amylin bidders-sources | Reuters

Medical / Pharmaceutical : PharmaGossip

via (Reuters) - AstraZeneca Plc (AZN.L) and Bristol-Myers Squibb Co (BMY.N) are among several pharmaceutical giants that have submitted initial bids for Amylin Pharmaceuticals Inc (AMLN.O), the diabetes drugmaker that...

AstraZeneca sells EU, Latam gout drug rights to Gruenenthal

Business & Finance : Business Insider: Clusterstock

LONDON (Reuters) - AstraZeneca has sold the European and Latin American rights to its new gout drug Zurampic to private German drugmaker Gruenenthal for up to $230 million, following a similar disposal of U.S. rights to the medicine...

Valeant gets right to develop AstraZeneca's psoriasis drug

Business & Finance : Business Insider: Clusterstock

(Reuters) - Canada's Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab. The arrangement excl...


Copyright © 2016 Regator, LLC